PE20060291A1 - POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES - Google Patents

POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Info

Publication number
PE20060291A1
PE20060291A1 PE2005000599A PE2005000599A PE20060291A1 PE 20060291 A1 PE20060291 A1 PE 20060291A1 PE 2005000599 A PE2005000599 A PE 2005000599A PE 2005000599 A PE2005000599 A PE 2005000599A PE 20060291 A1 PE20060291 A1 PE 20060291A1
Authority
PE
Peru
Prior art keywords
posaconazole
microns
particles
infections
moldes
Prior art date
Application number
PE2005000599A
Other languages
Spanish (es)
Inventor
Sydney Ugwu
Varda Sandweiss
Catherine Hardalo
Leonore Witchey-Lakshmanan
Zaiqi Wang
Marco Taglietti
Gopal Krishna
Roberta S Hare
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20060291A1 publication Critical patent/PE20060291A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

REFERIDA A UNA FORMULACION INYECTABLE ESTERILIZADA POR AUTOCLAVE, QUE COMPRENDE UNA SUSPENSION ACUOSA DE POSACONAZOL, ESTABILIZADA POR UN FOSFOLIPIDO, EN UNA MEZCLA QUE CONTIENE UN PROTECTOR TERMICO Y UN SISTEMA TAMPON. EL SISTEMA TAMPON CONTIENE UN TAMPON ORGANICO TAL COMO HISTIDINA, ACIDO CITRICO, GLICINA, CITRATO DE SODIO, ENTRE OTROS, EL CUAL PERMITE MANTENER UN PH DE ENTRE 3 A 9; EL FOSOFOLIPIDO PUEDE SER NATURAL Y/O SINTETICO TAL COMO 1-PALMITOIL-2-OLEOIL-SN-GLICERO-3-FOSFOCOLINA (POPC); Y EL PROTECTOR TERMICO CONTIENE TREHALOSA. EL POSACONAZOL TIENE UNA DISTRIBUCION GRANULOMETRICA CUYA MEDIANA ESTA ENTRE 1,0 Y 8,0 MICRONES, CON NO MAS DE 3000 PARTICULAS DE 10 MICRONES O DE MAYOR TAMANO, NI MAS DE 300 PARTICULAS DE 25 MICRONES O DE MAYOR TAMANO. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE INFECCIONES TALES COMO CANDIDIASIS OROFARINGEA O ESOFAGICA, ASPERGILOSIS INVASIVA, INFECCIONES CAUSADAS POR HONGOS DIMORFICOS, ZIGOMICOSIS E INFECCIONES INVASIVAS DEBIDAS A MOHOS Y LEVADURAS POCO FRECUENTES, ENFERMEDAD DE CHAGAS Y LEISHMANIASIS, ENTRE OTRASREFERRED TO AN INJECTABLE FORMULATION STERILIZED BY AUTOCLAVE, INCLUDING AN AQUEOUS SUSPENSION OF POSACONAZOLE, STABILIZED BY A PHOSPHOLIPID, IN A MIXTURE CONTAINING A THERMAL PROTECTOR AND A BUFFER SYSTEM. THE BUFFER SYSTEM CONTAINS AN ORGANIC BUFFER SUCH AS HISTIDINE, CITRIC ACID, GLYCINE, SODIUM CITRATE, AMONG OTHERS, WHICH ALLOWS TO MAINTAIN A PH OF BETWEEN 3 TO 9; THE PHOSOPHOLIPID MAY BE NATURAL AND / OR SYNTHETIC SUCH AS 1-PALMITOIL-2-OLEOIL-SN-GLYCERO-3-PHOSPHOCOLINE (POPC); AND THE THERMAL PROTECTOR CONTAINS TREHALOSE. POSACONAZOLE HAS A MEDIUM GRANULOMETRIC DISTRIBUTION WHICH IS BETWEEN 1.0 AND 8.0 MICRONS, WITH NO MORE THAN 3000 PARTICLES OF 10 MICRONS OR LARGER SIZE, NOR MORE THAN 300 PARTICLES OF 25 MICRONS OR LARGER SIZE. SUCH FORMULATION IS USEFUL IN THE TREATMENT OF INFECTIONS SUCH AS OROPHARYNGEAL OR ESOPHAGEAL CANDIDIASIS, INVASIVE ASPERGILLOSIS, INFECTIONS CAUSED BY DIMORPHIC FUNGI, ZYGOMYCOSIS AND INVASIVE INFECTIONS DUE TO MOLDES AND FRESH LEAVES, MOLDES AND LEAVES OF CHEMISTRY

PE2005000599A 2004-05-28 2005-05-27 POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES PE20060291A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57512604P 2004-05-28 2004-05-28

Publications (1)

Publication Number Publication Date
PE20060291A1 true PE20060291A1 (en) 2006-04-14

Family

ID=34971355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000599A PE20060291A1 (en) 2004-05-28 2005-05-27 POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES

Country Status (15)

Country Link
EP (1) EP1761247A1 (en)
JP (1) JP2008501034A (en)
KR (1) KR20070027564A (en)
CN (1) CN1988887A (en)
AR (1) AR049063A1 (en)
AU (1) AU2005249502A1 (en)
CA (1) CA2567803A1 (en)
IL (1) IL179627A0 (en)
MX (1) MXPA06013886A (en)
NO (1) NO20066005L (en)
PE (1) PE20060291A1 (en)
RU (1) RU2006146555A (en)
TW (1) TWI290051B (en)
WO (1) WO2005117831A1 (en)
ZA (1) ZA200609890B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009469A1 (en) * 2004-05-28 2006-01-12 Leonore Witchey-Lakshmanan Particulate-stabilized injectable pharmacutical compositions of posaconazole
RU2008148977A (en) 2006-05-12 2010-06-20 Фармакон-Форшунг Унд Бератунг Гмбх (At) APPLICATION OF COMBINED DRUGS CONTAINING ANTIFUNGIC AGENTS
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
CA2767489A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
JP5956980B2 (en) 2010-05-19 2016-07-27 サンド・アクチエンゲゼルシヤフト Process for the preparation of chiral compounds
EP2571871B1 (en) 2010-05-19 2017-06-21 Sandoz AG Process for the preparation of chiral triazolones
US9073904B2 (en) 2010-05-19 2015-07-07 Sandoz Ag Preparation of posaconazole intermediates
CA2798010C (en) 2010-05-19 2018-09-25 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
RS62583B1 (en) 2010-06-29 2021-12-31 Merck Sharp & Dohme Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
CN108329303A (en) 2011-06-16 2018-07-27 桑多斯股份公司 The method for preparing chipal compounds
CN103284959B (en) * 2012-02-22 2015-06-03 重庆圣华曦药业股份有限公司 Posaconazole freeze-dried powder injection and preparation method thereof
CN102755628B (en) * 2012-07-16 2013-10-23 中国科学院微生物研究所 Antifungal pharmaceutical composition
CN102805731B (en) * 2012-08-22 2014-04-30 北京莱瑞森医药科技有限公司 Posaconazole dry suspension and preparation method thereof
CN105030668B (en) * 2015-06-26 2018-03-27 济川药业集团有限公司 Oral posaconazole supensoid agent and preparation method thereof
CN106333925B (en) * 2015-07-10 2019-06-18 上海美悦生物科技发展有限公司 A kind of posaconazole liquid suspension and preparation method thereof
CN105997872B (en) * 2016-07-08 2019-02-19 河南省立眼科医院 A kind of antimycotic solution of ophthalmically acceptable nano-micelle containing posaconazole
CA3056919A1 (en) * 2017-03-26 2018-10-04 Vivi Robyn Stafford Method of treatment of skin conditions of eye lids
AU2018253189A1 (en) * 2017-04-12 2019-12-05 Vikash J. BHAGWANDIN Compositions, packaged pharmaceuticals, and methods of using posaconazole for the sensitization of resistant tumors
CN110507609B (en) * 2018-05-21 2021-09-17 上海医药工业研究院 Preparation method of posaconazole oral suspension
CN111514146A (en) * 2020-04-28 2020-08-11 山西振东泰盛制药有限公司 Pharmaceutical composition containing posaconazole
CN113933131B (en) * 2021-09-24 2024-01-26 合肥天一生物技术研究所有限责任公司 Vaginal microorganism fluorescent staining solution

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
JP4308902B2 (en) * 2001-04-03 2009-08-05 シェーリング コーポレイション Antifungal compositions with increased bioavailability

Also Published As

Publication number Publication date
EP1761247A1 (en) 2007-03-14
JP2008501034A (en) 2008-01-17
TW200609001A (en) 2006-03-16
AR049063A1 (en) 2006-06-21
CA2567803A1 (en) 2005-12-15
RU2006146555A (en) 2008-07-20
CN1988887A (en) 2007-06-27
KR20070027564A (en) 2007-03-09
AU2005249502A1 (en) 2005-12-15
ZA200609890B (en) 2008-09-25
MXPA06013886A (en) 2007-01-26
TWI290051B (en) 2007-11-21
NO20066005L (en) 2007-02-27
WO2005117831A1 (en) 2005-12-15
IL179627A0 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
PE20060291A1 (en) POSACONAZOLE INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH STABILIZED PARTICLES
PE20130589A1 (en) COMPOSITIONS AND METHODS FOR SUPPLYING THE CENTRAL NERVOUS SYSTEM OF ARYLSULFATASE A
AR092470A1 (en) ADALIMUMAB STABLE WATERPROOF FORMULATIONS
EA200901003A1 (en) FOAMING COMPOSITION FOR DESTRUCTION OF MEMBERS AND ITS APPLICATIONS
CL2015001973A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
PE20070437A1 (en) AQUEOUS FORMULATION hFSH
RU2011137204A (en) ANTISEPTIC COMPOSITIONS AND THEIR APPLICATIONS
PE20061154A1 (en) STABILIZED INJECTABLE PHARMACEUTICAL COMPOSITIONS WITH POSACONAZOLE PARTICULATES
EA201492021A1 (en) ANTI-COMPOSITION
PH12014502778B1 (en) Antibody formulation
CO6650381A2 (en) Meso-sized particulate pesticide compositions with enhanced activity
AR067011A1 (en) FORMULATIONS OF ANTIBODIES
CL2008003762A1 (en) Concentrated composition in aqueous suspension for crop protection, comprising an active compound and as stabilizing agents, a non-ionic dispersant and an anionic dispersant and water; methods for preparing said composition and uses thereof, for the care of crops of interest.
GT201200024A (en) SUBCUTANEOUS FORMULATION OF ANTI-HER2 ANTIBODY
AR081364A1 (en) PHARMACEUTICAL COMPOSITIONS OF PAZOPANIB AND METHODS FOR THEIR DEVELOPMENT
CL2018000033A1 (en) Composition to uncover a blocked nose that has antiviral activity.
EA201100896A1 (en) COMPOSITION INTENDED FOR SUCKING NICOTINE FROM THE FATAL CAVITY WITH THE PURPOSE TO STOP SMOKING
ECSP19072294A (en) PHARMACEUTICAL COMPOSITION INCLUDING SELEXIPAG
AR093218A1 (en) A WATERPROOF COMPOSITION INCLUDING DICAMBA AND A DERIVATIVE CONTROL AGENT
AR084318A1 (en) COMPOSITION THAT INCLUDES INSECTICIDE-WAX PARTICLES
PE20080994A1 (en) ANTIHISTAMINE SYRUP, STORAGE STABLE WITHOUT SUGAR
PE20191205A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING INSULIN
PE20060125A1 (en) DOSAGE FORMS AND PHARMACEUTICAL COMPOSITIONS INCLUDING 4-CYANE-N - {(2R) -2- [4- (2,3-DIHYDRO-BENZO [1,4] DIOXIN-5-IL) -PIPERAZIN-1-IL] -PROPIL] -N-PYRIDIN-2-IL-BENZAMIDE AND / OR RELATED COMPOUNDS
PE20181359A1 (en) CROP CARE AND PROTECTION COMPOSITION
EA201391555A1 (en) COMPOSITIONS OF SUSPENSION TYPE FOR LOCAL APPLICATION CONTAINING CYCLIC DEPSYPETPID

Legal Events

Date Code Title Description
FC Refusal